查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552861

法布瑞氏症治療市場規模、佔有率和趨勢分析報告：按解決方案、治療方法、給藥途徑、分銷管道、地區和細分市場預測，2024-2030年

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

法布瑞氏症治療市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，全球法布瑞氏症治療市場規模將達到49.3億美元，2024年至2030年複合年成長率為9.9%。

接受法布瑞氏症治療的患者數量不斷增加，Chaperone療法等新型治療方法的採用越來越多，以及基材減少療法和酵素替代療法等管道藥物的潛在核准，都為市場提供了動力。

法布瑞氏症治療是一種罕見的遺傳性溶小體貯積症，由抑制 α-半乳糖苷酶功能的基因突變所引起。法布瑞氏症的治療通常症狀輕微且起病緩慢，因此許多患者常常未被診斷出來。法布瑞氏症的標準治療方法是酵素替代療法（ERT）。賽諾菲的 Fabrazyme 和 Shire 的 Repregal 是唯一在歐盟核准的ERT，而 Fabrazyme 是唯一在美國核准的ERT。

目前臨床試驗的重點是提高 ERT 的安全性和有效性，並引入新型口服療法，以消除靜脈注射的需要。最近，Amicus Therapeutics 的 Galafold 在美國、加拿大、歐盟、日本、澳洲、以色列和韓國被核准為首個成人的口服Chaperone療法。

2017年，北美佔據法布瑞氏症治療市場最大佔有率，其次是歐洲。該地區的成長得益於新治療方法的高採用率、有利的報銷政策和改善的醫療設施。然而，Fabrazyme 等 ERT 治療的高成本在新興市場中構成了阻礙因素。

法布瑞氏症治療市場報告亮點

  • 靜脈注射在 2023 年佔據市場主導地位，市場佔有率為 65.9%，預計在 2024-2030 年預測期內將以最快的複合年成長率成長。
  • 酵素替代療法領域佔據市場主導地位，2023 年佔有率為 72.3%。
  • 2023年法布瑞氏症治療市場中，北美將佔最大佔有率，超過45.1%，其次是歐洲。
  • 預計亞太地區在預測期內成長最快，其次是拉丁美洲。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章法布瑞氏症治療市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 法布瑞氏症治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章法布瑞氏症治療市場：依治療方法估計與趨勢分析

  • 細分儀表板
  • 法布瑞氏症治療市場：治療方法變異分析，百萬美元，2023 年和 2030 年
  • 酵素替代療法
  • Chaperone治療
  • 基材減少療法
  • 其他

第5章法布瑞氏症治療市場：依途徑估計與趨勢分析

  • 細分儀表板
  • 法布瑞氏症治療市場：途徑變異分析，百萬美元，2023 年和 2030 年
  • 靜脈注射
  • 口服給藥

第6章法布瑞氏症治療市場：通路、前景、估計與趨勢分析

  • 細分儀表板
  • 法布瑞氏症治療市場：通路變化分析，百萬美元，2023 年和 2030 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章法布瑞氏症治療市場：區域估計與趨勢分析

  • 2023 年和 2030 年法布瑞氏症治療市場佔有率（按地區），百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Sanofi SA
    • Shire Plc.
    • Amicus Therapeutics Inc.
    • ISU Abxis Co Ltd.
    • JCR Pharmaceuticals Co Ltd.
    • Protalix Biotherapeutics Inc.
    • Idorsia Pharmaceuticals Ltd.
    • Avrobio Inc.
簡介目錄
Product Code: GVR-2-68038-747-6

Fabry Disease Treatment Market Growth & Trends:

The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.

Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi's Fabrazyme and Shire's Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.

Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics' Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.

North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.

Fabry Disease Treatment Market Report Highlights:

  • Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.
  • The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.
  • North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023
  • APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Fabry Disease Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Fabry Disease Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Fabry Disease Market: Treatment Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Fabry Disease Market: Treatment Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Enzyme Replacement Therapy
    • 4.3.1. Enzyme Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Chaperone Treatment
    • 4.4.1. Chaperone Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Substrate Reduction Therapy
    • 4.5.1. Substrate Reduction Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Diseases
    • 4.6.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Fabry Disease Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Fabry Disease Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Intravenous Route
    • 5.3.1. Intravenous Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral Route
    • 5.4.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Fabry Disease Market: Distribution Channel Outlook Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Fabry Disease Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Fabry Disease Market: Regional Estimates & Trend Analysis

  • 7.1. Fabry Disease Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. South Korea Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Thailand
      • 7.4.8.1. Thailand Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Sanofi S.A.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Shire Plc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Amicus Therapeutics Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. ISU Abxis Co Ltd.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. JCR Pharmaceuticals Co Ltd.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Protalix Biotherapeutics Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Idorsia Pharmaceuticals Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Avrobio Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives